Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by University of Alabama at Birmingham
Onyx Pharmaceuticals
Information provided by (Responsible Party):
Luciano Jose Costa, MD, University of Alabama at Birmingham Identifier:
First received: July 17, 2012
Last updated: September 29, 2015
Last verified: September 2015

This study is for patients that have multiple myeloma that has come back or relapsed and their condition indicates a procedure called an Autologous Hematopoietic Stem Cell Transplantation (AHSCT). AHSCT is a procedure when stem cells from bone marrow or blood are removed before high-dose chemotherapy. Afterwards, the removed stem cells are put back into the patient's body to form a new population of blood cells.

The high-dose chemotherapy administered before the AHSCT is called "Conditioning Therapy." The FDA has approved the use of the drug melphalan as a conditioning therapy. This research study will look at whether adding the study drug called carfilzomib will improve participant outcomes. Carfilzomib is considered investigational and is not approved by the FDA for the treatment of relapsed multiple myeloma.

This study is divided into two phases.

Phase I: Dose Escalation Phase:

The main purpose of Part I of this study is to examine the safety of the study drug, carfilzomib, and determine the safest amount of the study drug that can be given to subjects who have multiple myeloma. Subjects on this study will receive different dose levels of the study drug. If you are one of the first three subjects to receive the study drug, it will be at what is called the 'starting dose' for the study which is the lowest dose that is expected to be tolerated based on prior research. After the first set of participants receive the study drug, the study doctor will review their health to see how they are tolerating the treatment. This will decide if the study drug dosage will be increased or decreased for the next set of subjects who join the study. It is anticipated that 12- 18 participants will enroll in the Phase I portion of this study.

Phase II: Safety Confirmation Phase:

Once the study doctor has discovered the highest possible dose of study drug that subjects can tolerate, up to 28 more subjects may be enrolled at that dose level. The main purpose of the Phase II portion of the study is look at how effective the combination of carfilzomib and melphalan when given before your stem cell transplantation is in treating multiple myeloma. This expansion phase will also include evaluation of two single agent carfilzomib maintenance therapy regimens for patients without disease progression at day 100.

Condition Intervention Phase
Multiple Myeloma
Drug: Carfilzomib
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1/2A Study Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • To determine the Maximum Tolerated Dose (MTD) of carfilzomib plus melphalan as conditioning for AHSCT in patients with relapsed Multiple Myeloma(MM) [Phase I portion of study] [ Time Frame: 4 1/2 months ] [ Designated as safety issue: Yes ]
  • To evaluate efficacy of carfilzomib plus melphalan conditioning in patients with relapsed MM [ Time Frame: 4 1/2 months ] [ Designated as safety issue: Yes ]
  • To evaluate toxicity and tolerability of carfilzomib plus melphalan conditioning in patients with relapsed MM. [ Time Frame: 4 1/2 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To investigate the pharmacodynamic effects of carfilzomib + high dose melphalan in terms of changes in expression of fanconi anemia/BRCA DNA repair genes and DNA fragmentation [ Time Frame: 4 1/2 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 58
Study Start Date: May 2012
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Carfilzomib + high dose melphalan
Single arm.
Drug: Carfilzomib
Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. On day -2, with 60 to 120 minutes of the end of infusion of carfilzomib, subjects will receive 200 mg/m2 of intravenous melphalan as an intravenous push or a fast infusion, according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.

  Show Detailed Description


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥ 18 years and ≤ 70 years
  2. Life expectancy ≥ 12 months
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  4. Diagnosis of symptomatic multiple myeloma, relapsed after initial therapy.
  5. At least minimal response (defined as 25% decrease in the M protein in serum or urine) to the most recent treatment regimen.
  6. Evaluable disease prior to most recent treatment regimen as defined by at least one of the following:

    • Serum monoclonal (M) protein ≥0.5 g/dl by protein electrophoresis

      • 200 mg of M protein in the urine on 24 hour electrophoresis
    • Serum immunoglobulin free light chain ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
    • Monoclonal bone marrow plasmacytosis ≥30%
  7. Adequate hepatic function, with serum ALT ≤ 3.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg/dL (34 µmol/L) within 14 days prior to start of therapy
  8. Hemoglobin ≥ 8 g/dL (80 g/L) within 14 days prior to registration (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
  9. Creatinine clearance (CrCl) ≥ 40 mL/minute within 14 days prior to registration, either measured or calculated using a standard formula (eg, Cockcroft and Gault).
  10. Prior storage of at least 2 x 106 CD34+ cells/kg available for autologous transplantation. During the phase 1 component of the study, at least the same amount of cells is required as "back up" in the unlikely event of non-engraftment.
  11. Subjects may have had a prior AHSCT for the treatment of MM as long as it was performed greater than 12 months from study registration.
  12. Subjects must meet institutional general eligibility criteria for autologous transplantation.
  13. Written informed consent in accordance with federal, local, and institutional guidelines.
  14. Female of childbearing potential (FCBP) must agree to ongoing pregnancy testing and to practice contraception.
  15. Male subjects must agree to practice contraception.

Exclusion Criteria:

  1. Pregnant or lactating females.
  2. Major surgery within 30 days prior to start of treatment.
  3. Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to registration.
  4. Known human immunodeficiency virus infection.
  5. Active hepatitis B or C infection.
  6. Unstable angina or myocardial infarction within 4 months prior to registration, NYHA Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker.
  7. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to registration.
  8. Nonhematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas.
  9. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to registration.
  10. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
  11. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to registration.
  12. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01690143

Contact: Kathryn A Brooks, RN 205-996-8023
Contact: Pamela Dixon, RN 205-975-5387

United States, Alabama
UAB Recruiting
Birmingham, Alabama, United States, 35294
Contact: Kathryn Brooks, RN    205-996-8023   
Contact: Lisa Williams, RN    205-934-0066   
Principal Investigator: Luciano Costa, MD         
United States, New York
Memorial Sloan Kettering Cancer Center Not yet recruiting
New York, New York, United States, 10065
Contact: Sergio Giralt, MD    212-639-6009      
Principal Investigator: Heather Landau, MD         
United States, South Carolina
Medical University of South Carolina Hollings Cancer Center Not yet recruiting
Charleston, South Carolina, United States, 29425
Contact: Sarah Christopher    843-792-8856   
Contact: Tricia Bentz, CCRP    843-792-1753   
Principal Investigator: Saurah Chhabra, MD         
Sub-Investigator: Robert Stuart, MD         
Sub-Investigator: Yubin Kang, MD         
United States, Wisconsin
Medical College of Wisconsin Not yet recruiting
Milwaukee, Wisconsin, United States, 53226
Principal Investigator: Parameswaran Hari, MD         
Sponsors and Collaborators
University of Alabama at Birmingham
Onyx Pharmaceuticals
Principal Investigator: Luciano Costa, MD University of Alabama at Birmingham
  More Information

No publications provided

Responsible Party: Luciano Jose Costa, MD, Associate Professor of Medicine, University of Alabama at Birmingham Identifier: NCT01690143     History of Changes
Other Study ID Numbers: CTO 101669, Onyx IST-CAR-536
Study First Received: July 17, 2012
Last Updated: September 29, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Vascular Diseases
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 24, 2015